Parkinson’s disease is associated with the formation of protein aggregates called amyloid fibrils. α-synuclein amyloid accumulation is known to be a key factor in the development of neuronal degenerative diseases in the brain, and exploring some toxic compounds with biomedical application like copper oxide (CuO) nanoparticles that can promote protein aggregation and underlying cytotoxicity are the focus of preventive care studies in Parkinson’s disease. https://doi.org/10.1016/j.molliq.2020.115051